Key result
Proteomic biomarkers and aggregate biomarker panels show promise for improving cardiovascular risk prediction, although individual biomarkers have demonstrated only modest predictive ability to date.
Aggregate biomarker panels currently offer the most promising approach for improving cardiovascular risk prediction beyond traditional algorithms.
Panels may enhance risk prediction; leaves open clinical adoption pending prospective validation.
Cardiovascular disease (CVD) is the leading cause of mortality in the modern world. Traditional risk algorithms may miss up to 20% of CVD events. Therefore, there is a need for new cardiac biomarkers. Many fields of research are dedicated to improving cardiac risk prediction, including genomics, transcriptomics and proteomics. To date, even the most promising biomarkers have only demonstrated modest associations and predictive ability. Few have undergone randomized control trials. A number of biomarkers are targets to new therapies aimed to reduce cardiovascular risk. Currently, some of the most promising risk prediction has been demonstrated with panels of multiple biomarkers. This article reviews the current state and future of proteomic biomarkers and aggregate biomarker panels.
No takes yet. Share an insight, caveat, or question.
MacNamara et al. (2015) conducted a review in Cardiovascular disease. Proteomic biomarkers and aggregate biomarker panels was evaluated. Proteomic biomarkers and aggregate biomarker panels show promise for improving cardiovascular risk prediction, although individual biomarkers have demonstrated only modest predictive ability to date.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: